We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+8.51%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$7.52B
AUM Growth
+$1.2B
(+19%)
Cap. Flow
+$726M
Cap. Flow
% of AUM
9.65%
Top 10 Holdings %
Top 10 Hldgs %
19.11%
Holding
866
New
79
Increased
318
Reduced
279
Closed
56
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$75M |
| 2 |
Biogen
BIIB
|
+$70.7M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$60.1M |
| 4 |
Merck
MRK
|
+$54.6M |
| 5 |
Gilead Sciences
GILD
|
+$33.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$19.1M |
| 2 |
IRBT
iRobot
IRBT
|
+$15.5M |
| 3 |
Quest Diagnostics
DGX
|
+$15.4M |
| 4 |
Colgate-Palmolive
CL
|
+$14.8M |
| 5 |
Philip Morris
PM
|
+$12.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 33.26% |
| 2 | Technology | 16.05% |
| 3 | Financials | 11.26% |
| 4 | Consumer Discretionary | 7.98% |
| 5 | Communication Services | 7.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FNSR
201
DELISTED
Finisar Corp
FNSR
| $9.37M | 0.12% |
492,032
+21,564
| +5% | +$401K |
|
|
APLS
202
DELISTED
Apellis Pharmaceuticals
APLS
| $9.17M | 0.12% |
515,700
+275,700
| +115% | +$5.1M |
|
203
Booking.com
BKNG
$138B
| $9.05M | 0.12% |
114,050
-6,225
| -5% | -$490K |
|
|
MRTX
204
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $9.04M | 0.12% |
192,000
+99,300
| +107% | +$5.53M |
|
|
IMGN
205
DELISTED
Immunogen Inc
IMGN
| $9.02M | 0.12% |
952,500
+258,500
| +37% | +$2.48M |
|
206
Fortive
FTV
$19B
| $9M | 0.12% |
169,488
-225,902
| -57% | -$11.6M |
|
207
Charter Communications
CHTR
$14.7B
| $9M | 0.12% |
27,609
+3,986
| +17% | +$1.22M |
|
208
Omnicom Group
OMC
$22.7B
| $8.92M | 0.12% |
131,149
+59,857
| +84% | +$4.2M |
|
|
FCE.A
209
DELISTED
Forest City Realty Trust, Inc.
FCE.A
| $8.85M | 0.12% |
+352,600
| New | +$8.59M |
|
|
ARNA
210
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $8.83M | 0.12% |
191,970
+93,470
| +95% | +$3.79M |
|
211
CEVA Inc
CEVA
$1.01B
| $8.76M | 0.12% |
304,798
+13,652
| +5% | +$412K |
|
212
Ultragenyx Pharmaceutical
RARE
$2.65B
| $8.63M | 0.11% |
113,100
+28,100
| +33% | +$2.29M |
|
213
Coty
COTY
$2.33B
| $8.5M | 0.11% |
676,843
+32,233
| +5% | +$417K |
|
214
NextEra Energy
NEE
$187B
| $8.44M | 0.11% |
201,380
-21,780
| -10% | -$927K |
|
215
Hewlett Packard
HPE
$63.2B
| $8.39M | 0.11% |
514,293
-669,272
| -57% | -$10.7M |
|
|
XYZ
216
Block Inc
XYZ
$45.9B
| $8.35M | 0.11% |
84,281
-61,905
| -42% | -$4.77M |
|
217
D.R. Horton
DHI
$41B
| $8.34M | 0.11% |
197,782
+23,900
| +14% | +$1.03M |
|
218
Corpay
CPAY
$24.2B
| $8.33M | 0.11% |
36,578
+13,243
| +57% | +$2.89M |
|
219
Theravance Biopharma
TBPH
$874M
| $8.32M | 0.11% |
+254,700
| New | +$6.94M |
|
220
BorgWarner
BWA
$13.2B
| $8.32M | 0.11% |
220,883
+114,256
| +107% | +$4.49M |
|
221
Marathon Petroleum
MPC
$90.3B
| $8.21M | 0.11% |
102,629
+3,604
| +4% | +$285K |
|
222
American Water Works
AWK
$26.3B
| $8.12M | 0.11% |
92,275
-29,211
| -24% | -$2.57M |
|
223
Reinsurance Group of America
RGA
$15.7B
| $7.93M | 0.11% |
54,860
-336
| -0.6% | -$47.5K |
|
|
LJPC
224
DELISTED
La Jolla Pharmaceutical Company
LJPC
| $7.9M | 0.11% |
392,300
+47,000
| +14% | +$1.23M |
|
225
Phillips 66
PSX
$82.9B
| $7.89M | 0.1% |
70,011
-9,401
| -12% | -$1.09M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q3 2018 Portfolio in Review
As of Q3 2018, Candriam SCA held 866 positions worth $7.52B, up 19% from $6.32B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Candriam SCA deployed $726M of net new capital in Q3 2018, opening 79 new positions and adding to 318 existing holdings. Its largest new stake was Varonis Systems: 541,092 shares worth $13.2M.
By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 25% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Advanced Micro Devices, an estimated $19.1M trimmed.
- Candriam SCA's largest Q3 2018 buy was Varonis Systems: 541,092 shares worth $13.2M.
- Candriam SCA added most to Amgen in Q3 2018, an estimated $75M increase.
- Candriam SCA's biggest Q3 2018 reduction was Advanced Micro Devices, cutting an estimated $19.1M.
- Candriam SCA fully exited iRobot in Q3 2018, selling an estimated $15.5M.
- Candriam SCA's ten largest holdings make up 19% of its $7.52B portfolio in Q3 2018.
- Candriam SCA opened 79 new positions and closed 56 in Q3 2018.
- Candriam SCA's portfolio value rose 19% quarter-over-quarter to $7.52B.
Based on Candriam SCA's 13F filing for Q3 2018, filed 7 Nov 2018.